Company news

CNS Pharmaceuticals, Inc. news in 2024

CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

December 4, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV after Failure of Standard First Line Therapy

November 26, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

November 24, 2024

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

November 17, 2024

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 14, 2024

Quarterly Report for Quarter Ending September, 30, 2024 (Form 10-Q)

November 14, 2024

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

November 3, 2024

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

October 31, 2024

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At the Market under Nasdaq Rules

October 24, 2024

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At The Market Under Nasdaq Rules Form 8 K

October 22, 2024

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

October 22, 2024

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

October 9, 2024

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

October 7, 2024

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

September 22, 2024

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

September 11, 2024

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

August 26, 2024

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

August 21, 2024

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 14, 2024

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

July 29, 2024

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

July 24, 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

July 15, 2024

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

July 2, 2024

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

June 25, 2024

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 19, 2024

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 15, 2024

CNS Pharmaceuticals to Present at the LSX World Congress 2024

April 22, 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

April 21, 2024

CNS Pharmaceuticals to Present at Two Investor Conferences in April

March 31, 2024

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

March 31, 2024

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

January 28, 2024

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

January 17, 2024

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

January 16, 2024

Decks in 2024